Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study

ConclusionsNGS allows for broad, rapid, highly specific analyses of genomic regions. These results support use of the Extended RAS Panel as a companion diagnostic for selecting patients for panitumumab, and utilization is consistent with recent clinical guidelines regarding mCRCRAS testing. Overall, approximately 13% more patients were detected with the Extended RAS Panel versusKRAS exon 2 alone.Clinical trial registry identifierNCT00364013 (ClinicalTrials.gov).
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research